Cargando…

Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction

Recent studies send an unambiguous signal that the class of agents known as sodium-glucose–linked co-transporter-2 inhibitors (SGLT2i) prevent heart failure hospitalization in patients with type 2 diabetes. However, the mechanisms remain unclear. Herein the authors utilize a rodent model of heart fa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Connelly, Kim A., Zhang, Yanling, Visram, Aylin, Advani, Andrew, Batchu, Sri N., Desjardins, Jean-François, Thai, Kerri, Gilbert, Richard E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	MINI FOCUS ON SGLT2 INHIBITOR
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390677/ https://www.ncbi.nlm.nih.gov/pubmed/30847416 http://dx.doi.org/10.1016/j.jacbts.2018.11.010

Ejemplares similares

Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
por: Lim, Ven G., et al.
Publicado: (2019)

Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial
por: Satirapoj, Bancha, et al.
Publicado: (2019)

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2019)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

How can sodium–glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron‐deficient? Implications for understanding iron homeostasis in heart failure
por: Packer, Milton
Publicado: (2022)

Dapagliflozin's effect on serum homocysteine in patients with hypertension complicated with insulin resistance
por: Yu, Xiaoqian, et al.
Publicado: (2023)

Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
por: Connelly, Kim A., et al.
Publicado: (2020)

Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study
por: Okada, Kenta, et al.
Publicado: (2020)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2018)

Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study
por: Kario, Kazuomi, et al.
Publicado: (2020)

Deconvoluting Kinase Inhibitor Induced Cardiotoxicity
por: Lamore, Sarah D., et al.
Publicado: (2017)

Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats
por: Kim, Sua, et al.
Publicado: (2019)

Suppression of NLRP3 Inflammasome Activation Ameliorates Chronic Kidney Disease-Induced Cardiac Fibrosis and Diastolic Dysfunction
por: Bugyei-Twum, Antoinette, et al.
Publicado: (2016)

Impact of climate change on vector- and rodent-borne infectious diseases
por: Beermann, Sandra, et al.
Publicado: (2023)

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
por: Habibi, Javad, et al.
Publicado: (2017)

Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction
por: Connelly, Kim A., et al.
Publicado: (2018)

The Goto Kakizaki rat: Impact of age upon changes in cardiac and renal structure, function
por: Meagher, Patrick, et al.
Publicado: (2021)

Bone loss and the aromatase inhibitors
por: Lester, J, et al.
Publicado: (2005)

Potential use of COX-2–aromatase inhibitor combinations in breast cancer
por: Bundred, N J, et al.
Publicado: (2005)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

The effects of aromatase inhibitors on lipids and thrombosis
por: Bundred, N J
Publicado: (2005)

Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats
por: Ala, Moein, et al.
Publicado: (2022)

Systolic, diastolic blood pressure and pulse pressure and risk of stroke in young aged patients with atrial fibrillation
por: Lee, S R, et al.
Publicado: (2023)

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
por: Butler, Javed, et al.
Publicado: (2022)

Repeated treatment with bone marrow cell secretory products maintains long-term renoprotection in experimental chronic kidney disease: a placebo-controlled trial
por: Yuen, Darren A., et al.
Publicado: (2015)

Early-Outgrowth Bone Marrow Cells Attenuate Renal Injury and Dysfunction via an Antioxidant Effect in a Mouse Model of Type 2 Diabetes
por: Zhang, Yanling, et al.
Publicado: (2012)

Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial
por: Voors, Adriaan A., et al.
Publicado: (2022)

Motile kinetochores and polar ejection forces dictate chromosome position on the vertebrate mitotic spindle
Publicado: (1994)

Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial
por: Böhm, Michael, et al.
Publicado: (2022)

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
por: Hao, Zhengyang, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
por: Sang, Haiqiang, et al.
Publicado: (2022)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible
por: Sciatti, Edoardo, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England
por: Kolovos, Spyros, et al.
Publicado: (2023)

Micro-CT analysis of the rodent jaw bone micro-architecture: A systematic review
por: Faot, F., et al.
Publicado: (2015)

Massive Air Embolism During Atrial Fibrillation Ablation: Averting Disaster in a Time of Crisis
por: Do, Duc H., et al.
Publicado: (2021)

Severe Right Ventricular Failure Following Pericardiocentesis: A Case Report of Pericardial Decompression Syndrome
por: Perez, Sergio A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hq3vbbs9at829hp66isuujlsug